Position in GH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$87,572,511
+$47,373,087 QoQ
Shares Held
583,700
+34.1% QoQ
Ownership
0.435%
of shares outstanding
% of Portfolio
1.73%
of 13F equity value
Holder Rank
#51
of 594 holders
Holding Since
Sep 2020
11 quarters on record
Voting authority
Sole 25%
Shared 0%
None 75%
Common Shares in GH Over Time
Shares Held
Position Value (USD)
Derivatives in GH
reported options exposure · as of Jun 30, 2022CallValue
$2,017,000
CallShares
50,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026ORBIMED ADVISORS LLC holds $219,279,875 across 4 Diagnostics & Research names. GH ranks #1 (39.9% of the industry book) .
All Filings in GH
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $87,572,511 | 583,700 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $40,199,424 | 435,200 | Shares | Defined | 2026-05-15 | |
| 2022-09-30 | $53,420,892 | 992,400 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $2,017,000 | 50,000 | Call | Defined | 2022-08-15 | |
| 2022-06-30 | $41,687,356 | 1,033,400 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $87,794,496 | 1,325,400 | Shares | Defined | 2022-05-16 | |
| 2021-12-31 | $122,764,548 | 1,227,400 | Shares | Defined | 2022-02-14 | |
| 2021-09-30 | $153,437,274 | 1,227,400 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $152,430,806 | 1,227,400 | Shares | Defined | 2021-08-16 | |
| 2021-03-31 | $149,200,110 | 977,400 | Shares | Defined | 2021-05-17 | |
| 2020-12-31 | $69,363,216 | 538,200 | Shares | Defined | 2021-02-16 | |
| 2020-09-30 | $17,247,654 | 154,300 | Shares | Defined | 2020-11-16 | |
| No filing history on record for this holder in this stock. | ||||||